Skip to Content
Merck
All Photos(1)

Key Documents

111M-1

Sigma-Aldrich

CD11c (5D11) Mouse Monoclonal Antibody

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

5D11, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (111M-14)
vial of 0.5 mL concentrate (111M-15)
bottle of 1.0 mL predilute (111M-17)
vial of 1.0 mL concentrate (111M-16)
bottle of 7.0 mL predilute (111M-18)

manufacturer/tradename

Cell Marque

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:20-1:80

isotype

IgG2a

control

bone marrow, hairy cell leukemia

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic

Gene Information

human ... ITGAX(3687)

General description

CD11c is an adhesion receptor of the leukocyte function-associated family of molecules. This cell surface antigen is normally expressed on granulocytes, monocytes, natural killer cells, and small populations of T- and B-lymphocytes. Therefore, the control for antibody validation and verification should be bone marrow and acute inflammatory tissue blocks. Anti-CD11c, clone 5D11, detects a formalin-resistant epitope of CD11c antigen and will now provide a significant change to the way hairy cell leukemia (HCL) can be diagnosed and assessed in FFPE. The tumor cells of the majority of other types of small B-cell lymphoma do not express this CD11c antigen. HCL is a distinctive yet uncommon chronic B-cell lymphoproliferative disorder, predominantly involving the bone marrow and spleen. Bone marrow aspiration and trephine biopsy are necessary for making a definitive diagnosis and treatment of hairy cell leukemia (HCL) although in exceptional cases, the diagnosis of HCL is made by histological analysis of splenic tissue after splenectomy or splenic needle core biopsy. However, aspiration is successful in only approximately 10% of patients. The marrow films obtained may demonstrate the presence of hairy cells but definitive diagnosis usually requires a bone marrow trephine biopsy due to the high frequency of a dry tap on aspiration. When there is difficulty in obtaining a good marrow aspirate, (frequent occurrence of a dry tap), examination of bone marrow trephine histology together with immunohistochemical analysis is the only available method to make a definitive diagnosis of HCL. Confirmation of the nature of the infiltrate can be obtained by immunocytochemistry performed on paraffin sections using antibodies against CD20, T bet, DBA.44 and TRAcP. However, expression of both TRAcP and DBA.44 (CD72) is not specific for HCL. It should also be noted, when undertaking immunohistochemistry to support a diagnosis of HCL in trephine biopsy sections, that up to 50% of cases show nuclear positivity for cyclin D1although confusion with mantle cell lymphoma (MCL) is less likely for an experienced hematopathologist as the cytology and histology of MCL are different from HCL. Korinna et al. in a recent study used clone (5D11) of anti-CD11c to investigate 31 bone marrow trephines with low-level HCL infiltrates and showed that the anti-CD11c was able to detect HCL to a level of 2% of tumor cells in BM biopsies. This indicates that immunohistochemical staining of formalin-fixed, decalcified bone marrow trephine biopsies with anti-CD11c can be used both for early diagnosis of HCL and for detection of residual disease following therapy. It is important to note that the CD11c-positive interstitial macrophages, which were generally more weakly stained than the hairy cells, did not interfere with the identification of the more strongly stained tumor cells. Among malignant lymphomas, CD11c is consistently expressed in HCL, although it is also rarely detected in B-CLL/small lymphocytic lymphoma, and nodal and extranodal marginal zone lymphoma (MZL).

Quality


IVD

IVD

IVD

RUO

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Philip Th Went et al.
The American journal of surgical pathology, 29(4), 474-478 (2005-03-16)
Because of marrow fibrosis, bone marrow aspirations are often nonconclusive in patients with hairy cell leukemia (HCL). Therefore, histologic examination is important in HCL but often difficult in cases with low numbers of tumor cells. A combined immunohistochemical positivity for
R N Miranda et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 13(12), 1308-1314 (2001-01-06)
Mantle cell lymphoma (MCL) is more aggressive when compared with other lymphomas composed of small, mature B lymphocytes. Cyclin D1 is overexpressed in MCL as a result of the translocation t(11;14)(q13;q32). Cyclin D1 immunohistochemistry in fixed, paraffin-embedded tissue contributes to
G Marotta et al.
Leukemia & lymphoma, 37(1-2), 145-149 (2000-03-18)
This study analyzed the expression of the beta2 integrin CD11c in 155 patients with well-characterized B-cell chronic lymphoproliferative disorders: 106 B-cell chronic lymphocytic leukemias (B-CLL), 21 hairy cell leukemias (HCL), 9 B-cell prolymphocytic leukemias (PLL) and 19 low grade non-Hodgkin's
Gail Jones et al.
British journal of haematology, 156(2), 186-195 (2011-11-25)
The British Committee for Standards in Haematology first produced guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant in 2000. This revision updates those guidelines and covers the areas of diagnosis, treatment and assessment
Korinna Johrens et al.
Pathobiology : journal of immunopathology, molecular and cellular biology, 75(4), 252-256 (2008-06-27)
The diagnosis of hairy cell leukemia (HCL) and its distinction from other B-cell lymphomas can be difficult in formalin-fixed tissue. This is because the histology is not always classical, and despite having a characteristic phenotype, there are few relevant monoclonal

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service